Drug Trial Radar · NCT06427395
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
102
Actual
Start
Jul 16, 2024
Primary completion
Apr 18, 2027
Study completion Jul 18, 2027
Sponsor
- Lead sponsor
- Zydus Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- May 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
Conditions
- Primary Biliary Cholangitis
Interventions
Saroglitazar Magnesium 1 mgDrug
Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0Time frame: From baseline to 24 Months/EOT
Locations
28 sites in 3 countries. Site status is shown where the registry gives one.
Zydus US013
Los Angeles, California
Zydus US011
Pasadena, California
Zydus US043
Sacramento, California
Zydus US022
Aurora, Colorado
Zydus US037
New Haven, Connecticut
Zydus US027
Jacksonville, Florida
Zydus US006
Lakewood Rch, Florida
Zydus US005
Miami, Florida
Zydus US020
Marietta, Georgia
Zydus US001
Indianapolis, Indiana
Zydus US035
Rochester, New York
Zydus US002
Charlotte, North Carolina
Zydus US042
Houston, Texas
Zydus US031
Murray, Utah
Zydus US016
Charlottesville, Virginia
Zydus US039
Richmond, Virginia
Zydus US033
Seattle, Washington
Zydus AR001
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Zydus AR007
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Zydus AR006
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Zydus AR005
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Zydus AR003
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Zydus AR004
Pilar, Buenos Aires, Argentina
Zydus TR016
Altındağ, Turkey (Türkiye)
Zydus TR004
Ankara, Turkey (Türkiye)
Zydus TR005
Bursa, Turkey (Türkiye)
Zydus TR017
Cebeli, Turkey (Türkiye)
Zydus TR015
Melikgazi, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.